Upcoming Events

Nymox Association Conventions

November 8, 2017:

Nymox Pharmaceutical Corporation  is pleased to announce an important upcoming symposium and panel discussion on its first-in-class investigational drug NX-1207, currently in late stage Phase 3 for benign prostatic hyperplasia (BPH) and Phase 2 for Prostate Cancer. The symposium will be held during the 2018 Annual Meeting of the American Urological Association in San Diego CA 3:00 p.m. May 5 in the San Diego Convention Center.

Nymox Reports Successful Results:

November 8, 2017:

HASBROUCK HEIGHTS, NJ (October 11, 2016) Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce successful new study results from the long-term repeated injection group from the U.S. Phase 3 trials for fexapotide, the Company’s lead compound in late stage development for enlarged prostate (BPH) and for localized prostate cancer. The aim of the study was to determine the safety and clinical benefit fexapotide can provide to men who were given a second injection of fexapotide for their prostate enlargement (BPH).

In the new study long-term outcomes were determined in 344 patients who were given a single repeat fexapotide treatment after initial blinded treatment with fexapotide or placebo. Patients were followed for 2 to 6.5 years (mean 4.2 years) after initial treatment. All treatment failures were included in the analysis. Results have now shown that there was long-term statistically significant symptomatic improvement (mean improvement of 6.5 points in the AUA BPH Symptom Score) compared to Phase 3 patients who received placebo alone (p<.001). Repeat injection was found to be safe with no significant drug related toxicities or side effects found in the study.

Nymox Announces Private Placements

November 8, 2017:

HASBROUCK HEIGHTS, NJ (August 9, 2017) Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is
pleased to announce recent completion of private placements with proceeds totaling US $3.0 million. There
were no warrants or fees associated with the transactions. The placements were with long-term
shareholders of the Company, and will be used for general corporate purposes.

The Company announced on August 7 that an important large symposium and panel discussion of the
Company’s new drug Fexapotide Triflutate will be held at the September meeting of the American
Urological Association, Mid-Atlantic Section. The September symposium at the AUA meeting will feature
presentations from prominent Fexapotide Clinical Trial urologists, and will include panel discussions of data
and results from the U.S. Fexapotide trials undertaken in 2009-2017. The Chairperson of the Symposium
will be Ronald Tutrone MD, FACS of Chesapeake Urology, Towson, MD.